Am J Cardiol:急性冠脉综合征和缺血性卒中危险因素相似

2013-05-07 高晓方 译 医学论坛网

  希腊一项研究表明,急性冠脉综合征和缺血性卒中的相关危险因素基本相似,因此有有利于同时实施一级预防措施。论文4月29日在线发表于《美国心脏病学杂志》(Am J Cardiol)。   此项研究共纳入250例首次急性冠脉综合征患者、250例首次缺血性卒中患者以及500例基于人群的对照者;以1:1比率依据年龄和性别配对。对吸烟/被动吸烟、心血管疾病家族史、无体育活动、高血压、糖

  希腊一项研究表明,急性冠脉综合征和缺血性卒中的相关危险因素基本相似,因此有有利于同时实施一级预防措施。论文4月29日在线发表于《美国心脏病学杂志》(Am J Cardiol)。

  此项研究共纳入250例首次急性冠脉综合征患者、250例首次缺血性卒中患者以及500例基于人群的对照者;以1:1比率依据年龄和性别配对。对吸烟/被动吸烟、心血管疾病家族史、无体育活动、高血压、糖尿病、高胆固醇血症、超重和肥胖、特质焦虑以及地中海膳食依从等心血管疾病危险因素加以评估。受试者对上述危险因素的重要性认知进行分级。

  结果显示,吸烟和高胆固醇血症为效应最强的急性冠脉综合征危险因素;对于卒中而言则为焦虑和心血管疾病家族史(P 均<0.01)。对急性冠脉综合征和卒中各危险因素的比值比进行比较可发现非显著性差异,但吸烟除外。基于受试者的健康观念,吸烟和压力为最重要的危险因素,但受试者均将被动吸烟分级为次要危险因素。

卒中相关的拓展阅读:


Comparative Analysis of Cardiovascular Disease Risk Factors Influencing Nonfatal Acute Coronary Syndrome and Ischemic Stroke
Abstract
The aim of the present work was to compare the influence of classic cardiovascular disease (CVD) risk factors on the development of acute coronary syndrome (ACS) and ischemic stroke. During 2009-2010, 1,000 participants were enrolled: 250 were consecutive patients with a first ACS, 250 were consecutive patients with a first ischemic stroke, and 500 were population-based, control subjects, 1-for-1 matched to the patients by age and gender. The following CVD risk factors were evaluated: smoking/passive smoking, family history of CVD, physical inactivity, hypertension, hypercholesterolemia, diabetes mellitus, presence of overweight and obesity, trait anxiety (assessed with the Spielberger State-Trait Anxiety Inventory form Y-2), and adherence to the Mediterranean diet (assessed by the MedDietScore). Furthermore, participants graded the perceived significance of the aforementioned factors, using a scale from 1 (not important) to 9 (very important). The risk factors with the highest effect size for ACS, as determined by the Wald criterion, were smoking and hypercholesterolemia; regarding stroke, they were anxiety and family history of CVD (all p <0.01). When the odds ratios of each factor for ACS and stroke were compared, insignificant differences were observed, except for smoking. On the basis of the participants' health beliefs, smoking and stress emerged as the most important risk factors, whereas all subjects graded passive smoking as a least important factor. In conclusion, similarities of the risk factors regarding ACS and ischemic stroke facilitate simultaneous primary prevention measures.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1805965, encodeId=3fc7180596570, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat May 11 09:23:00 CST 2013, time=2013-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781624, encodeId=8ba81e81624c2, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Jan 29 12:23:00 CST 2014, time=2014-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892572, encodeId=0fae18925e276, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Aug 24 06:23:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430375, encodeId=2d7214303e524, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu May 09 00:23:00 CST 2013, time=2013-05-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1805965, encodeId=3fc7180596570, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat May 11 09:23:00 CST 2013, time=2013-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781624, encodeId=8ba81e81624c2, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Jan 29 12:23:00 CST 2014, time=2014-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892572, encodeId=0fae18925e276, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Aug 24 06:23:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430375, encodeId=2d7214303e524, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu May 09 00:23:00 CST 2013, time=2013-05-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1805965, encodeId=3fc7180596570, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat May 11 09:23:00 CST 2013, time=2013-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781624, encodeId=8ba81e81624c2, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Jan 29 12:23:00 CST 2014, time=2014-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892572, encodeId=0fae18925e276, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Aug 24 06:23:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430375, encodeId=2d7214303e524, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu May 09 00:23:00 CST 2013, time=2013-05-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1805965, encodeId=3fc7180596570, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat May 11 09:23:00 CST 2013, time=2013-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781624, encodeId=8ba81e81624c2, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Jan 29 12:23:00 CST 2014, time=2014-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892572, encodeId=0fae18925e276, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Aug 24 06:23:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430375, encodeId=2d7214303e524, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu May 09 00:23:00 CST 2013, time=2013-05-09, status=1, ipAttribution=)]

相关资讯

FDA拒绝批准利伐沙班用于降低ACS患者心脏病和中风发作风险

  强生日前表示,FDA再次拒绝公司旗下利伐沙班用于降低急性冠脉综合征患者心脏病发作和卒中风险的新适应证。   利伐沙班是强生与德国制药商拜耳共同开发的一个产品,早在去年6月份利伐沙班的这一适应证就曾被FDA拒绝过,当时FDA的专家小组对该产品缺失的试验数据和出血风险表示担忧。针对这种情况,强生向FDA补充了利伐沙班临床试验中退出受试者的风险效益数据。   “虽然我们看到利伐沙班严重出血的风险

NEJM:靶向抑制血小板以澄清急性冠脉综合征的更佳药物治疗方案

  背景  对于无ST段抬高并且未进行血运重建的不稳定型心绞痛或心肌梗死患者,强化血小板抑制的效果尚未被描述。   方法  在这项双盲、随机试验中,在主要分析(包括7243例年龄<75岁且接受阿司匹林治疗的患者)中,我们评估了普拉格雷(10 mg/d)和氯吡格雷(75 mg/d)治疗长达30个月的效果比较。在次要分析(包括2083 例年龄≥75 岁的患者)中,我们评估了普拉格

Am Heart J:EPICOR研究有望明确ACS患者的抗血栓药物应用模式

  欧洲学者正在实施的EPICOR研究将显示急性冠脉综合征(ACS)患者住院期间和出院后的抗血栓药物应用模式,并可借此探讨不同用药模式下临床转归、生活质量和医疗费用的潜在差异。论文于2012年11月21日在线发表于《美国心脏杂志》(Am Heart J)。   前瞻性、多中心、观察性EPICOR研究对因ACS住院患者进行为期2年的出院后随访。此项研究的目的在于描述抗血栓药物应

NEJM:Dalcetrapib对近期有急性冠脉综合征的稳定性冠心病患者的疗效

  背景  在观察性分析中,较高水平的高密度脂蛋白胆固醇(HDL-C)与冠心病事件的较低危险相关。然而,通过治疗升高的HDL-C水平是否降低心血管危险尚不确定。抑制胆固醇酯转运蛋白(CETP)可使HDL-C水平升高,因此有可能改善心血管转归。   方法  我们随机分配15871 例近期有过急性冠脉综合征的患者,除接受最佳可用循证医疗之外,还接受600 mg/d 的CETP 抑

Am J Cardiol:急性冠脉综合征和缺血性卒中危险因素相似

  希腊一项研究表明,急性冠脉综合征和缺血性卒中的相关危险因素基本相似,因此有有利于同时实施一级预防措施。论文4月29日在线发表于《美国心脏病学杂志》(Am J Cardiol)。   此项研究共纳入250例首次急性冠脉综合征患者、250例首次缺血性卒中患者以及500例基于人群的对照者;以1:1比率依据年龄和性别配对。对吸烟/被动吸烟、心血管疾病家族史、无体育活动、高血压、糖

AJC: 非梗阻性与梗阻性冠心病的ACS患者远期死亡相似

  意大利学者的一项研究表明,合并非梗阻性冠状动脉疾病(CAD)的急性冠脉综合征(ACS)患者持续存在长期复发缺血事件的高风险。论文于4月22日在线发表于《美国心脏病学杂志》(Am J Cardiol)。   研究旨在评估ACS合并非梗阻性CAD或梗阻性CAD患者经皮冠状动脉介入治疗(PCI)后患病率、长期转归和口服抗血小板治疗药的依从性。以血管造影显示任何主要心外膜动脉血管